c-CRAF Inhibitors
2 drugsAbout c-CRAF
c-CRAF (RAF1) is a serine/threonine kinase in the RAS/MAPK pathway, regulating cell growth, proliferation, differentiation, and survival. Its position in the MAPK pathway makes it a key signaling node.
c-CRAF is a drug development target, particularly in oncology, but there is no genetic evidence data available linking c-CRAF mutations to specific diseases.
c-CRAF is targeted by two FDA-approved small molecule drugs: SORAFENIB TOSYLATE (Viatris) and NEXAVAR (Bayer). These drugs have applications in oncology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Fibrolamellar Carcinoma with only 2 trials.
- phase2 represents biological uncertainty with 57% completion.
Top c-CRAF Drugs
The c-CRAF drug market is concentrated between Viatris and Bayer.
High market concentration suggests potential entry barriers for new companies.
c-CRAF Drug Modality Landscape
Modalities
Routes of Administration
c-CRAF is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs may offer differentiation.
c-CRAF Clinical Trials 379 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 155 | 113 | 33 | 8 | 77% |
| Phase 2 | 166 | 98 | 46 | 21 | 68% |
| Phase 3 | 53 | 34 | 11 | 8 | 76% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
c-CRAF Drug Approval Timeline (2005 - 2020)
The first c-CRAF drug was approved in 2005, with the most recent in 2020.
The approval timeline suggests a potentially maturing market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 113 clinical trials targeting c-CRAF.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities